Inhibrx, Inc. (INBX)

34,06 -0,03 (-0,09%) Börsenschluss: 04:00PM EDT

Inhibrx, Inc.

11025 North Torrey Pines Road
Suite 200 Torrey Pines Science Park
La Jolla, CA 92037
United States
858 795 4220
https://inhibrx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 166

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Mark Paul Lappe	Founder, Chairman, President & CEO	1,1M	N/A	1968
Dr. Brendan P. Eckelman Ph.D.	Founder & Chief Scientific Officer	769,25k	N/A	1980
Ms. Kelly Devine Deck B.S., CPA, M.S.	Executive VP & CFO	636,87k	N/A	1981
Mr. Quinn L. Deveraux	Founder	N/A	N/A	N/A
Dr. Ashraf Amanullah	Executive VP & Chief Technical Operations Officer	N/A	N/A	1968
Ms. Leah Pollema J.D.	VP, Corporate Secretary & General Counsel	N/A	N/A	N/A
Dr. Charbel Helaihel Pharm.D.	Vice President of Marketing & Commercial Planning	N/A	N/A	N/A
Mr. Jeffrey J. Jensen	Executive VP & Chief Clinical Operations Officer	N/A	N/A	N/A
Mr. David Matly M.B.A.	Executive VP and Chief Commercial & Business Development Officer	N/A	N/A	N/A
Dr. Carlos Bais Ph.D.	Executive Vice President of Translational Sciences	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Corporate Governance

Inhibrx, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 9, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.